GlobeNewsWire
02 Oct 2026, 11:30 UTC · 6h ago
Verdict
Headline takes no side. We score CYTK +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
Cytokinetics plans to submit a Supplemental New Drug Application for aficamten in non-obstructive HCM in Q4 2026.
Newpress release dated Oct 02, 2026
So whatApproval would expand the addressable patient population beyond the current oHCM indication, directly impacting FY2027 peak sales estimates.
More positive than 93% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
The company will present Late Breaking Clinical Research results from the ACACIA-HCM trial on October 12, 2026.
Newpress release dated Oct 02, 2026
So whatDetailed efficacy and exercise performance data presented within 10 days will serve as the primary catalyst for the stock ahead of the sNDA filing.
More positive than 79% of claims this week
Cytokinetics will present results from the SEQUOIA-HCM trial regarding right ventricular function and pulmonary coupling on October 10, 2026.
Newpress release dated Oct 02, 2026
More positive than 53% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
The company is presenting positive clinical trial data and planning a Supplemental New Drug Application for aficamten.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2h ago
−1.3%
Price is moving against the score
$64.78 vs $65.62 close before publication (Oct 1) · not market-adjusted
CYTK chart →
